Neutropenia News and Research

RSS

Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils, the most important type of white blood cell, in the blood.

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

30 Nov 2012

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).

30 Nov 2012

European Medicines Agency accepts Exelixis’ COMETRIQ MAA for review

Exelixis, Inc. today announced the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for COMETRIQ (cabozantinib) for the proposed indication of treatment of progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).

29 Nov 2012

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Seattle Genetics, Inc. announced today that ADCETRIS (brentuximab vedotin) has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of mycosis fungoides (MF). MF is the most common type of cutaneous T-cell lymphoma (CTCL).

26 Nov 2012

Bevacizumab ruled out for stage III colorectal cancer

Findings from the AVANT trial do not support the use of bevacizumab in patients receiving oxaliplatin-based chemotherapy for resected stage III or high-risk stage II colon carcinoma.

19 Nov 2012

Adding bortezomib ‘boosts acute myeloid leukemia chemotherapy response’

Older patients with untreated acute myeloid leukemia may benefit from having bortezomib added to daunorubicin and cytarabine during induction therapy and to consolidation intermediate-dose cytarabine, the results of a US study indicate.

14 Nov 2012

Sapacitabine tolerated, efficacious in elderly leukemia patients

The nucleoside analog sapacitabine appears to be “active and tolerable” in elderly patients with acute myeloid leukemia, say authors of a phase II study reported in the Lancet Oncology.

5 Nov 2012

Treatment rate high at end of life for prostate cancer patients

Approximately one-third of men with castration-resistant prostate cancer receive some form of treatment in the last 3 months of life, show US study results.

1 Nov 2012

FDA accepts Sunovion’s two LATUDA sNDAs for review

Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental New Drug Applications (sNDAs) for the use of LATUDA as 1) monotherapy and 2) adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression).

31 Oct 2012

Procalcitonin good marker of bacteremia in children with central lines

High procalcitonin levels are a good indicator of bacteremia in children with a central venous catheter who present to the emergency department with fever, suggest study findings.

30 Oct 2012

Pfizer receives FDA approval for Synribo to treat chronic myelogenous leukemia

The U.S. Food and Drug Administration today approved Synribo (omacetaxine mepesuccinate) to treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease.

29 Oct 2012

Genzyme announces key data from AUBAGIO Phase III trial on multiple sclerosis

Genzyme, a Sanofi company announced today that key data from the TOWER trial were presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

15 Oct 2012

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

15 Oct 2012

Lenalidomide worsens survival, adverse events in prostate cancer

A combination of lenalidomide plus docetaxel and prednisone treatment in patients with chemotherapy-naive prostate cancer leads to worse overall survival rates and increased toxicity compared with placebo, show study results.

12 Oct 2012

USPTO grants five-year extension to Spectrum's FOLOTYN patent

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the United States Patent and Trademark Office (USPTO) has extended by five years the U.S. Patent No. 6,028,071, which covers FOLOTYN (pralatrexate injection).

8 Oct 2012

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, and Seattle Genetics, Inc., today announced preliminary data from one arm of a three arm phase I, open-label, multicenter study designed to determine the safety and activity of sequential and combination treatment approaches of brentuximab vedotin with CHOP or CH-P chemotherapy in newly diagnosed patients with CD30-positive mature T- and NK- cell lymphomas.

1 Oct 2012

Exelix reports preliminary data from cabozantinib phase 1 study on solid tumors

Exelixis, Inc. today reported preliminary data from an ongoing phase 1 dose escalation study of cabozantinib in Japan.

1 Oct 2012

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Eli Lilly and Company today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC).

1 Oct 2012

EC approves Janssen’s DACOGEN for treatment of de novo acute myeloid leukaemia

Janssen-Cilag International NV announced today that the European Commission has approved the marketing authorisation for DACOGEN(decitabine) for the treatment of adult patients (age 65 years and above) with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organisation (WHO) classification, who are not candidates for standard induction chemotherapy.

28 Sep 2012

OncoGenex commences custirsen Phase 3 trial in non-small cell lung cancer

OncoGenex Pharmaceuticals, Inc. announced today the initiation of ENSPIRIT, a Phase 3 trial evaluating custirsen for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have progressed after initial chemotherapy treatment has failed.

28 Sep 2012